We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 26, 2022

First-Line ICI Therapy and Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era

JAMA Network Open

 

Additional Info

JAMA Network Open
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era
JAMA Netw Open 2022 Aug 01;5(8)e2225459, N Lamba, PA Ott, JB Iorgulescu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading